Candel Therapeutics (NASDAQ: CADL) entered into a product commercialization agreement with EVERSANA, a global commercialization services provider, to support the potential U.S. launch of its lead product, aglatimagene besadenovec, for intermediate‑to‑high‑risk localized prostate cancer.
Under the agreement, EVERSANA will deliver a comprehensive suite of services—including data and analytics, medical affairs, market access, and field operations—to build the commercial infrastructure needed for a U.S. launch. The partnership builds on Candel’s existing collaboration with IDEA Pharma, a division of SAI MedPartners, and is designed to accelerate the company’s path to regulatory approval and commercial readiness.
The deal is a key step toward Candel’s planned Biologics License Application (BLA) submission in Q4 2026. Aglatimagene has received Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA for this indication, positioning it for an expedited review process. The partnership underscores Candel’s partner‑led commercial strategy, allowing the company to focus on science and regulatory progress while leveraging EVERSANA’s expertise to reach patients efficiently.
Candel has secured significant financial resources to support its commercialization efforts, including a $130 million term loan facility and a $100 million royalty‑funding agreement. Cash reserves are projected to fund operations through Q1 2028. The U.S. addressable market for aglatimagene in prostate cancer is estimated at $10–$16 billion, and the treatment landscape has seen minimal innovation over the past two decades, creating a substantial unmet need. Recent FDA approvals such as Akeega, Nubeqa, and Pluvicto illustrate the active therapeutic area and the potential for aglatimagene to capture market share.
"From the beginning, we designed Candel's commercial strategy around a partner‑led model that allows us to stay focused on advancing the science and navigating the regulatory pathway, while having access to world‑class commercial capabilities on demand," said Dr. Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel Therapeutics. "With the addition of EVERSANA, that model is fully in place, and with the progress we've already made across our pre‑commercialization workstreams, we have confidence in our readiness for the potential commercial launch of aglatimagene for the treatment of intermediate‑to‑high‑risk, localized prostate cancer." He added, "This non‑dilutive strategic financing will support the U.S. launch of aglatimagene besadenovec, assuming FDA approval, and will allow us to further invest in what we believe will be a world class commercial program."
The partnership is expected to accelerate Candel’s path to regulatory approval and commercial readiness, enabling the company to bring a potentially transformative therapy to patients while maintaining financial flexibility and capital efficiency.
revised_sentiment_rating":6} }
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.